{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
acetohydroxamic acid
to a specific field?
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
SB-206606 (better known as BRL-37344) was developed by Beecham Pharmaceuticals and is currently licensable from GlaxoSmithKline. SB-206606 is an agonist for the Beta-3 adrenergic receptor with an EC 50 value of 17 nM (human B3AR expressed in CHO cells). SB-206606 was in pre-clinical development as a potential treatment of Diabetes Mellitus, although such efforts have been discontinued. Recently it has also garnered some interest as a potential treatment for alcoholism.
Apocholic acid is a product of mild dehydration of cholic acid. Apocholic acid is powerful complexing and enolizing agent, giving stable addition-compounds (“choleric acids”) with numerous organic molecules. It was shown, that apocholic acid is able to produce tumors in situ. Apocholic acid was found to have a decreasing effect on the cholesterol level of both the plasma and the liver of rats.
![Structure of 2-(1-Methylethoxy)ethyl 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzoate hydrochloride](/img/832ac166-f8c4-4e50-a127-22995bd57e07.svg?size=200&context=yufsrttoii)
